Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.

@article{Rio2007GeneES,
  title={Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.},
  author={M Del Rio and Franck Molina and C. Bascoul-Mollevi and Virginie Copois and Fr{\'e}d{\'e}ric Bibeau and Patrick Chalbos and Corinne Bareil and Andrew Kramar and Nicolas Salvetat and Caroline Fraslon and Emmanuel Conseiller and Virginie Granci and B. LeBlanc and Bernard Pau and P. Martineau and Marc Ychou},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 7},
  pages={773-80}
}
PURPOSE In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
In patients with advanced colorectal cancer , leucovorin , fluorouracil , and irinotecan ( FOLFIRI ) is considered as one of the reference first - line treatments .
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin , fluorouracil , and irinotecan .
Colorectal CarcinomaDisease has accepted treatment with regimenFolinic Acid-Fluorouracil-Irinotecan Regimen
After validation in an independent cohort of patients , our gene signature could be used as a decision tool to assist oncologists in selecting colorectal cancer patients who could benefit from FOLFIRI chemotherapy , both in the adjuvant and the first - line metastatic setting .
In patients with advanced colorectal cancer , leucovorin , fluorouracil , and irinotecan ( FOLFIRI ) is considered as one of the reference first - line treatments .
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin , fluorouracil , and irinotecan .
In patients with advanced colorectal cancer , leucovorin , fluorouracil , and irinotecan ( FOLFIRI ) is considered as one of the reference first - line treatments .
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin , fluorouracil , and irinotecan .
In patients with advanced colorectal cancer , leucovorin , fluorouracil , and irinotecan ( FOLFIRI ) is considered as one of the reference first - line treatments .
All Topics